ArticleThe Journal of infection2024
Global genomic diversity of Pseudomonas aeruginosa in bronchiectasis.
Article in The Journal of infection, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07088926 (A Phase IIb Randomized, Double-blind, Placebo-controlled, Parallel, Multidose Study to Evaluate the Efficacy, Safety, and PK of AZD0292 in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase IIb Randomized, Double-blind, Placebo-controlled, Parallel, Multidose Study to Evaluate the Efficacy, Safety, and PK of AZD0292 in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
Who cites it
12 citing papers in PubMed.
- Treatable traits-based management of bronchiectasis: moving from theory to clinical practice.Chinese medical journal pulmonary and critical care medicine · 2026Review
- Applicability of Nanopore-only whole-genome sequencing forJournal of clinical microbiology · 2026Article
- Therapeutic Potential of Ginkgolic Acid C17:1 in Modulating PTEN/mtDNA/TLR9 Axis for Alleviating Chronic Pseudomonas Aeruginosa Infection in Bronchiectasis.Iranian journal of biotechnology · 2026Article
- Genomic Analysis of Ocular Pseudomonas aeruginosa Isolates: Insights From a Predominantly Asian, Multi-Regional Dataset.Investigative ophthalmology & visual science · 2026Article
- An integrated computational-experimental approach identifies Malate Synthase G as therapeutic target to disrupt carbon metabolism in chronic Pseudomonas aeruginosa infection.Functional & integrative genomics · 2026Article
- Bronchiectasis in the precision medicine era: pathogenesis and therapeutic advances.Journal of thoracic disease · 2026Review
- Single-bacterial cell insights into mechanisms of ceftriaxone resistance in Neisseria subflava.Nature communications · 2026Article
- Molecular characteristics of chromosome-mediated colistin resistance in carbapenem-resistant Pseudomonas aeruginosa isolates from a tertiary hospital in China.BMC microbiology · 2026Article
- Genomic variants distinguish Pseudomonas aeruginosa from cystic fibrosis sputum and bloodstream infection.BMC infectious diseases · 2026Article
- Bacteria-phage infection network structure and genomic defence system content predict efficacy of a phage therapy cocktail againstPhilosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025Article
- Sputum metagenomics in bronchiectasis reveals pan-European variation: an EMBARC-BRIDGE study.The European respiratory journal · 2025Article
- Whole Genome Analysis of Ocular Pseudomonas aeruginosa Isolates Reveals Genetic Diversity.Investigative ophthalmology & visual science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectivesPseudomonas aeruginosa is the most common pathogen in the bronchiectasis lung, associated with worsened outcomes. P. aeruginosa genomic studies in this context have been limited to single-country, European studies. We aimed to determine strain diversity, adaptation mechanisms, and AMR features to better inform treatment.
methodsP. aeruginosa from 180 bronchiectasis patients in 15 countries, obtained prior to a phase 3, randomised clinical trial (ORBIT-3), were analysed by whole-genome sequencing. Phylogenetic groups and sequence types were determined, and between versus within patient genetic diversity compared using Analysis of Molecular Variance (AMOVA). The frequency of AMR-associated genes and mutations was also determined.
resultsA total of 2854 P. aeruginosa isolates were analysed, predominantly belonging to phylogenetic group 1 (83%, n = 2359). Genetic diversity was far greater between than within patients, responsible for >99.9% of total diversity (AMOVA: phylogroup 1: df = 145, P < 0.01). Numerous pathways were under selection, some shared with CF (e.g., motility, iron acquisition), some unique to bronchiectasis (e.g., novel efflux pump PA1874). Multidrug resistance features were also frequent.
conclusionsWe present a 10-fold increase in the availability of genomic data for P. aeruginosa in bronchiectasis, highlighting key distinctions with cystic fibrosis and potential targets for future treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.